Eva Polverino (Hospital Vall d'Hebron, Vall d'Hebron Research Institute [VHIR], Respiratory Disease Department, Barcelona, Spain) shares her expert clinical perspectives on the current challenges for diagnosis and treatment of nontuberculous mycobacteria (NTM) infections and how to optimise patient management moving forward.
Questions1. What are the main factors to consider when nontuberculous mycobacteria (NTM) is suspected in patients with bronchiectasis? (0:12)
2. Why are current NTM guidelines poorly adhered to in clinical practice? (1:07)
3. How can use of a multidisciplinary team ensure improved diagnosis and patient management in NTM lung disease? (2:06)
4. What are the main limitations of current treatment options for patients with NTM and bronchiectasis? (3:08)
5. What are the emerging treatment options in NTM infection? (3:48)
6. Why are these infections increasing? (4:49)
Speaker disclosure: Eva Polverino has nothing to disclose in relation to this video interview.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018, supported by an unrestricted independent educational grant from Insmed.